Kelun-Biotech’s Sac-TMT shows breakthrough results in first-line lung cancer trial
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Call it a ray of hope for those enduring the pain of knee osteoarthritis -- the most common form of arthritis, affecting over 300 million people worldwide
CD388 is administered as a single 450-milligram subcutaneous dose in adults and adolescents
The deal accelerates GE HealthCare’s digital transformation, expanding its reach into outpatient care and enterprise imaging—a $2 billion-plus growth market
Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options
Millions of stroke survivors across the world may soon have a new defense
The therapy -- Ryoncil (remestemcel-L-rknd) -- will be tested in adults with severe steroid-refractory acute graft-versus-host disease
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
Subscribe To Our Newsletter & Stay Updated